Related Experiment Videos
Dark adaptation in patients with Best vitelliform macular dystrophy
W Baca1, G A Fishman, K R Alexander
1Department of Ophthalmology and Visual Sciences, University of Illinois, Chicago College of Medicine 60612.
The British Journal of Ophthalmology
|June 1, 1994
Summary
Patients with Best vitelliform macular dystrophy (BVMD) exhibit normal dark adaptation recovery times in clinically normal retina. This contrasts with Stargardt macular dystrophy, indicating distinct functional differences despite shared lipofuscin accumulation.
Area of Science:
- Ophthalmology
- Retinal Diseases
- Visual Psychophysics
Background:
- Best vitelliform macular dystrophy (BVMD) and Stargardt macular dystrophy are inherited retinal disorders.
- Both conditions involve lipofuscin accumulation in retinal pigment epithelial cells.
- Understanding functional differences is crucial for diagnosis and management.
Purpose of the Study:
- To investigate psychophysical dark adaptation in patients with BVMD.
- To compare dark adaptation recovery in BVMD with findings in Stargardt macular dystrophy.
- To differentiate functional characteristics of these two macular dystrophies.
Main Methods:
- Utilized Goldmann-Weekers dark adaptometry for psychophysical dark adaptation studies.
- Determined prebleach thresholds and assessed postbleach full recovery curves.
- Tested patients with clinically normal-appearing retina.
Main Results:
- All six patients with BVMD demonstrated normal dark adaptation recovery times to baseline thresholds after rod visual pigment bleaching.
- This normal recovery in BVMD contrasts with reported findings in Stargardt macular dystrophy.
- Functional recovery of rod dark adaptation thresholds differs between BVMD and Stargardt dystrophy.
Conclusions:
- BVMD patients show preserved rod dark adaptation function in unaffected retinal areas.
- Functional electrophysiological and psychophysical profiles distinguish BVMD from Stargardt macular dystrophy.
- Dark adaptation testing can aid in differentiating these lipofuscin-storage macular diseases.